Evaluation of the anti-Trypanosoma cruzi activity in vitro and in vivo of silibinin and silibinin in association to benznidazole.

Simple item page
dc.contributor.authorTorchelsen, Fernanda Karoline Vieira da Silva
dc.contributor.authorSilva, Thaila Martins
dc.contributor.authorMilagre, Matheus Marques
dc.contributor.authorSilva, Rafael Rodrigues
dc.contributor.authorReis, Levi Eduardo Soares
dc.contributor.authorBranquinho, Renata Tupinambá
dc.contributor.authorSilva, Glenda Nicioli da
dc.contributor.authorLana, Marta de
dc.date.accessioned2021-09-13T17:58:48Z
dc.date.available2021-09-13T17:58:48Z
dc.date.issued2020pt_BR
dc.description.abstractChagas disease (CD) is endemic in Latin America. Drugs available for its treatment are benznidazole (BZ)/nifurtimox (NF), both with low efficacy in the late infection and responsible for several side effects. Studies of new drugs for CD among natural products, and using drug combinations with BZ/NF are recommended. Silibinin (SLB) is a natural compound that inhibits the efflux pump (Pgp) of drugs in host cell membranes, causes death of trypanosomatids, has anti-inflammatory activity, and was never assayed against T. cruzi. Here, in vitro and in vivo activities of SLB, SLB+BZ, and BZ against T. cruzi Y strain were evaluated. Cytotoxicity of SLB in VERO cells by the MTT method revealed IC50 of 250.22 μM. The trypanocidal activity evaluated by resazurin method in epimastigotes showed that SLB 25 μM inhibited parasite growth. SLB IC50 and selectivity index (SI) for amastigote were 79.81 μM and 3.13, respectively. SLB100+BZ10 showed higher parasite inhibition (91.44%) than SLB or BZ. Swiss mice infected with Y strain were treated with SLB, SLB+BZ, and BZ. Parasitemia was evaluated daily and 90, 180, and 240 days after treatment in surviving animals by hemoculture, blood qPCR, and after euthanasia, by qPCR in heart tissue. SLB monotherapy was not able to control the parasitemia/mortality of the animals. Parasitological negativation of 85.7– 100% was observed in the experimental groups treated with SLB+BZ. Although SLB had shown activity against T. cruzi in vitro, it was not active in mice. Thus, the results of the therapeutic effect observed with SLB+BZ may be interpreted as a result from BZ action.pt_BR
dc.identifier.citationTORCHELSEN, F. K. V. da S. et al. Evaluation of the anti-Trypanosoma cruzi activity in vitro and in vivo of silibinin and silibinin in association to benznidazole. Parasitology Research, v. 120, p. 1511-1517, nov. 2020. Disponível em: <https://link.springer.com/article/10.1007/s00436-020-06944-5>. Acesso em: 10 jun. 2021.pt_BR
dc.identifier.doihttps://doi.org/10.1007/s00436-020-06944-5pt_BR
dc.identifier.issn1432-1955
dc.identifier.urihttp://www.repositorio.ufop.br/jspui/handle/123456789/13697
dc.identifier.uri2https://link.springer.com/article/10.1007/s00436-020-06944-5pt_BR
dc.language.isoen_USpt_BR
dc.rightsrestritopt_BR
dc.subjectDrug associationpt_BR
dc.titleEvaluation of the anti-Trypanosoma cruzi activity in vitro and in vivo of silibinin and silibinin in association to benznidazole.pt_BR
dc.typeArtigo publicado em periodicopt_BR
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
ARTIGO_EvaluationTrypanosomaCruzi.pdf
Size:
521.5 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
DEACL - Artigos publicados em periódicos